MX363119B - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX363119B
MX363119B MX2014013091A MX2014013091A MX363119B MX 363119 B MX363119 B MX 363119B MX 2014013091 A MX2014013091 A MX 2014013091A MX 2014013091 A MX2014013091 A MX 2014013091A MX 363119 B MX363119 B MX 363119B
Authority
MX
Mexico
Prior art keywords
insulin
subject
compound
combination
administration
Prior art date
Application number
MX2014013091A
Other languages
English (en)
Spanish (es)
Other versions
MX2014013091A (es
Inventor
Johansen Thue
Mersebach Henriette
Axelsen Mads
Lange Martin
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2014013091A publication Critical patent/MX2014013091A/es
Publication of MX363119B publication Critical patent/MX363119B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2014013091A 2012-05-01 2013-05-01 Composicion farmaceutica. MX363119B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12166252 2012-05-01
EP12166251 2012-05-01
US201261641544P 2012-05-02 2012-05-02
US201261641540P 2012-05-02 2012-05-02
PCT/EP2013/059073 WO2013164375A1 (en) 2012-05-01 2013-05-01 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
MX2014013091A MX2014013091A (es) 2014-12-08
MX363119B true MX363119B (es) 2019-03-11

Family

ID=49514218

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013091A MX363119B (es) 2012-05-01 2013-05-01 Composicion farmaceutica.

Country Status (9)

Country Link
US (1) US9884094B2 (enExample)
EP (1) EP2844274B1 (enExample)
JP (1) JP6262206B2 (enExample)
AU (1) AU2013255880B2 (enExample)
BR (1) BR112014026442A8 (enExample)
CA (1) CA2872083A1 (enExample)
MX (1) MX363119B (enExample)
RU (1) RU2670106C2 (enExample)
WO (1) WO2013164375A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー/エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
WO2014147141A1 (en) * 2013-03-20 2014-09-25 Novo Nordisk A/S Insulin dosing regimen
WO2014177623A1 (en) * 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
WO2016001185A1 (en) * 2014-07-02 2016-01-07 Novo Nordisk A/S Dosage regimen for the treatment of diabetes
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2021009027A1 (en) 2019-07-12 2021-01-21 Novo Nordisk A/S High concentration insulin formulation
US20250154220A1 (en) * 2023-11-15 2025-05-15 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
WO1990013540A1 (en) 1989-04-19 1990-11-15 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
PT792290E (pt) 1993-09-17 2002-01-30 Novo Nordisk As Insulina acilada
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
EP2287184A3 (en) 2003-08-05 2011-08-10 Novo Nordisk A/S Novel insulin derivatives
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
WO2007128817A2 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
CN101677947B (zh) 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
MY161892A (en) * 2008-02-19 2017-05-15 Biocon Ltd A method of obtaining a purified, biologically active heterologous protein
ES2607003T3 (es) * 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
CN103167878A (zh) * 2010-10-27 2013-06-19 诺沃—诺迪斯克有限公司 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病

Also Published As

Publication number Publication date
BR112014026442A8 (pt) 2018-01-16
JP6262206B2 (ja) 2018-01-17
WO2013164375A1 (en) 2013-11-07
RU2670106C2 (ru) 2018-10-18
MX2014013091A (es) 2014-12-08
US9884094B2 (en) 2018-02-06
BR112014026442A2 (pt) 2017-06-27
EP2844274B1 (en) 2019-03-20
RU2014147674A (ru) 2016-06-27
EP2844274A1 (en) 2015-03-11
CA2872083A1 (en) 2013-11-07
US20150126439A1 (en) 2015-05-07
AU2013255880A1 (en) 2014-10-16
AU2013255880B2 (en) 2017-07-20
JP2015517458A (ja) 2015-06-22

Similar Documents

Publication Publication Date Title
MX363119B (es) Composicion farmaceutica.
PH12019500517A1 (en) Long-acting formulations of insulins
PH12014500922A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
MX2022004041A (es) Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos.
MX375745B (es) Composicion para el tratamiento de la diabetes que comprende conjugado de analogo de insulina de accion prolongada y conjugado de peptido insulinotropico de accion prolongada.
MY183793A (en) Pharmaceutical compositions
NZ714273A (en) Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
WO2011087835A3 (en) Novel compositions and methods for treating inflammatory bowel disease and airway inflammation
NZ602380A (en) Peptides for vaccine against birch allergy
AU2010353685A8 (en) Novel glucagon like peptide analogs, composition, and method of use
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
MX2012010520A (es) Composicion antioxidante para reducir el estres oxidativo atribuible al tratamiento con farmacos anticonceptivos hormonales.
WO2013084070A3 (en) Salmonella vaccine proteins
WO2014018763A3 (en) Method of treating type i diabetes using apolipoprotein aiv
NZ707168A (en) Pharmaceutical composition of insulins
WO2011163321A3 (en) Composition and method of treating lipid encapsulated virus infections
WO2013090965A3 (de) Zusammensetzung enthaltend antikörper gegen gluten und gerbstoffe
HK1223834A1 (zh) 具有生物学活性的胰岛素衍生物
MX2015013160A (es) Metodo y productos para mejorar la absorcion celular de farmaco y suplementos dieteticos.
HK1229209A1 (en) Method and products for enhancing cellular uptake of drug and dietary supplements
NZ720788A (en) Eczema treatment
IN2013MU01157A (enExample)
WO2012025831A3 (en) Salmonella vaccine proteins